|
Affiliation |
Hospital Clinical Oncology |
Graduating School 【 display / non-display 】
-
2007.04-2011.03
Akita University Faculty of Medicine Graduated
-
2001.04-2005.03
Tokyo Institute of Technology Faculty of Science Graduated
Graduate School 【 display / non-display 】
-
2014.04-2019.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
-
2005.04-2007.03
The University of Tokyo Master's Course Completed
Campus Career 【 display / non-display 】
-
2022.04-Now
Akita University Hospital Clinical Oncology Specially-appointed Assistant Professor
-
2019.04-2022.03
Akita University School of Medicine Endowed Departments Assistant Professor appointed to endowed chairs
Thesis for a degree 【 display / non-display 】
-
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Shimazu K, Inoue M, Sugiyama S, Fukuda K, Yoshida T, Taguchi D, Uehara Y, Kuriyama S, Tanaka M, Miura M, Nanjyo H, Iwabuchi Y, Shibata H
Cancer science 109 ( 10 ) 3285 - 3293 2019.03
Single author
Research Achievements 【 display / non-display 】
-
Recent trends in bone metastasis treatments: A historical comparison using the new Katagiri score system.
Kenji Matsuda, Kazuhiro Shimazu, Hanae Shinozaki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Kyoko Nomura, Hiroyuki Shibata
World journal of clinical cases 12 ( 15 ) 2499 - 2505 2024.05
Research paper (journal)
BACKGROUND: Bone metastasis has various negative impacts. Activities of daily living (ADL) and quality of life (QOL) can be significantly decreased, survival may be impacted, and medical expenses may increase. It is estimated that at least 5% cancer patients might be suffering from bone metastases. In 2016, we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone Metastasis. Since then, the therapeutic outcomes for patients have gradually improved. As life expectancy is a major determinant of surgical intervention, the strategy should be modified if the prolongation of survival is to be achieved. AIM: To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone metastasis. METHODS: For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023, parameters including the site and number of bone metastases, laboratory data, and survival time, were extracted from electronic medical records and the Katagiri score was calculated. The association with survival was determined for each factor. RESULTS: Data from 136 patients were obtained. The 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0% in this study, which was 6% and an apparent improvement from 2014 when the scoring system was developed. Other factors significantly affecting survival included five or more bone metastases than less (P = 0.0080), and treatment with chemotherapy (P < 0.001), bone modifying agents (P = 0.0175) and immune checkpoint inhibitors (P = 0.0128). In recent years, advances in various treatment methods have extended the survival period for patients with advanced cancer. It is necessary not only to simply extend survival time, but also to maintain ADL and improve QOL. CONCLUSION: Various therapeutic interventions including surgical approach for bone metastasis, which is a disorder of locomotor organs, are increasingly required. Guidelines and scoring system for prognosis need to be revised promptly.
-
Taguchi D, Inoue M, Fukuda K, Yoshida T, Shimazu K, Fujita K, Okuyama H, Matsuhashi N, Tsuji A, Yoshida K, Miura M, Shibata H
International Journal of Clinical Oncology 2019.12 [Refereed]
Research paper (journal) Domestic Co-author
-
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Shimazu K, Inoue M, Sugiyama S, Fukuda K, Yoshida T, Taguchi D, Uehara Y, Kuriyama S, Tanaka M, Miura M, Nanjyo H, Iwabuchi Y, Shibata H
Cancer science 109 ( 10 ) 3285 - 3293 2018.08 [Refereed]
Research paper (journal) Domestic Co-author
-
Guillain-Barré syndrome in a cancer patient treated with bevacizumab.
Taguchi D, Kamada S, Yoshida T, Fukuda K, Shimazu K, Inoue M, Sugawara M, Nanjyo H, Iijima K, Shibata H
International Cancer Conference Journal 2018.05 [Refereed]
Research paper (journal) Domestic Co-author
-
Effect of anti-PD-1 antibody, nivolumab on early gastric cancer.
Fukuda K, Yoshida T, Shimazu K, Taguchi D, Inoue M, Nanjyo H, Shibata H.
International Cancer Conference Journal 2017.03
Research paper (journal) Domestic Co-author